ClinicalTrials.gg
CompletedNCT04109391Updated Oct 26, 2022Results posted

Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03

A Phase 3 interventional study of TX05 (trastuzumab) and Herceptin (trastuzumab) in HER2-positive Breast Cancer, Early-stage Breast Cancer and Breast Cancer, sponsored by Tanvex BioPharma USA, Inc.. Completed at 86 sites in 10 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-26.

Sponsored by Tanvex BioPharma USA, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
338
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
55th of 366
338 · median 61
Started
2019
with 14 others
Phase 3
60 of 374
3 open now
Registered
278th of 374
by date

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 55th largest by enrollment of the 366 interventional ones that give a count, is one of 15 that started in 2019, is one of 60 in phase 3, and was the 278th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This is an extension study to provide adjuvant treatment with single agent Herceptin or TX05 and assess continued safety and immunogenicity in subjects with HER2-positive early breast cancer following neoadjuvant treatment and surgical resection in Protocol TX05-03.

03

Conditions studied

  • HER2-positive Breast Cancer
  • Early-stage Breast Cancer
  • Breast Cancer
  • Breast Neoplasms
  • Stage II Breast Cancer
  • Stage IIIA Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written .
  • Females ≥ 18 years of age.
  • Completed treatment (regardless of treatment arm) in the TX05/ Herceptin neoadjuvant study and the investigator believes the subject requires continued access to single agent trastuzumab in order to continue deriving clinical benefit.
  • Successfully undergone surgical resection of their primary tumor with no evidence of residual disease (as determined by local assessment) and no other adjuvant therapy, other than trastuzumab, is planned. However, subjects will be allowed to receive hormonal therapy if they have hormone receptor positive tumors. Subjects will also be allowed to receive adjuvant radiation therapy, if required by their treating physician.
  • Able to comply with the study protocol.
  • Female subjects of must have a negative serum pregnancy test within 14 days of first administration of study drug and agree to use effective (hormonal contraceptive, intrauterine device, diaphragm with spermicide, or condom with spermicide) throughout the study period and for 7 months after last administration of study drug.

Exclusion criteria

Exclusion Criteria:

  • Breast cancer or residual disease post operatively (as determined by local assessment).
  • History or presence of a medical condition or disease that in the investigator's opinion would place the subject at an unacceptable risk for study participation.
  • Lactating or pregnant female.
  • Women of who do not consent to use highly effective methods of (e.g. true abstinence [periodic abstinence {e.g. calendar ovulation, symptothermal, post-ovulation methods} and withdrawal are not acceptable methods of contraception], sterilization, or other non-hormonal forms of contraception) during treatment and for at least 7 months after the last administration of study drug. Subjects must agree to not breast-feed while receiving study drug.
  • Any condition that in the opinion of the Investigator represents an obstacle for study conduct and/or represents a potential unacceptable risk for subjects.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
338 participants (actual)

Study arms

  • Experimental
    Test Product (TX05)

    IV trastuzumab (TX05) 8 mg/kg loading dose and then 6 mg/kg every 3 weeks for up to 13 cycles TX05 (trastuzumab): Subjects will receive up to 13 cycles of adjuvant treatment. These subjects received TX05 on the TX05-03 study and continued to receive TX05 in this extension study.

    Biological: TX05 (trastuzumab)

  • Active comparator
    Reference Therapy (Herceptin)

    IV trastuzumab (Herceptin) TX05 8 mg/kg loading dose and then 6 mg/kg every 3 weeks for up to 13 cycles Herceptin (trastuzumab): Subjects will receive up to 13 cycles of adjuvant treatment. These subjects received Herceptin on the TX05-03 study and were randomized to receive Herceptin in this extension study.

    Biological: Herceptin (trastuzumab)

  • Experimental
    Test Product (Herceptin/TX05 Transition)

    IV trastuzumab (TX05) 8 mg/kg loading dose and then 6 mg/kg every 3 weeks for up to 13 cycles TX05 (trastuzumab): Subjects will receive up to 13 cycles of adjuvant treatment. These subjects received Herceptin on the TX05-03 study and were randomized to receive TX05 in this extension study.

    Biological: TX05 (trastuzumab)

Interventions

06

What researchers measure

Primary outcomes

  1. Immunogenicity Assessments (ADA and Nab)

    Samples for the evaluation of anti-drug antibodies (ADA), including neutralizing antibodies (Nab) were obtained before the administration of Cycle 1 (Week 0), Cycle 6 (Week 15), and the EOT/ET Visit. Only subjects with a positive ADA result were further tested for ADA cross-reactivity and Nab. Only subjects with a positive Nab result were further tested for Nab cross-reactivity.

    Time frame: Assessed from first infusion through end of treatment (Week 45) or Early Termination visit. Each cycle is 3 weeks.

  2. Disease-Free Survival

    DFS, defined as the time from randomization in the neoadjuvant study (Protocol TX05-03) to the documentation of a first failure, where a failure was the recurrence of breast cancer or a diagnosis of a second primary cancer.

    Time frame: Through study completion/end of treatment (Week 45).

  3. Overall Survival

    OS, defined as the time from randomization in the neoadjuvant study (Protocol TX05-03) until death from any cause.

    Time frame: Through study completion/end of treatment (Week 45).

07

Results

Posted Oct 26, 2022

Participant flow

Participant flow — Overall Study
MilestoneTest Product (TX05 Only)Reference Therapy (Herceptin Only)Test Product (Herceptin/TX05 Transition)
Started1758281
Completed1657777
Not completed1054
Withdrew: Adverse event220
Withdrew: Withdrawal by subject200
Withdrew: Pregnancy100
Withdrew: Subject refused to continue, ae and 2 patients only received 10 of 13 cycles310
Withdrew: Lost to follow-up001
Withdrew: Lack of efficacy223

Outcome measures

PrimaryImmunogenicity Assessments (ADA and Nab)

Samples for the evaluation of anti-drug antibodies (ADA), including neutralizing antibodies (Nab) were obtained before the administration of Cycle 1 (Week 0), Cycle 6 (Week 15), and the EOT/ET Visit. Only subjects with a positive ADA result were further tested for ADA cross-reactivity and Nab. Only subjects with a positive Nab result were further tested for Nab cross-reactivity.

Time frame:
Assessed from first infusion through end of treatment (Week 45) or Early Termination visit. Each cycle is 3 weeks.
Reported as:
Count of participants · Participants
Immunogenicity Assessments (ADA and Nab)
ParticipantsTest Product (TX05 Only)Reference Therapy (Herceptin Only)Test Product (Herceptin/TX05 Transition)
Baseline — ADA Positive323
Baseline — Nab Positive000
Baseline — ADA Negative1597774
Baseline — Not evaluated1334
Cycle 6 Week 15 — ADA Positive114
Cycle 6 Week 15 — Nab Positive000
Cycle 6 Week 15 — ADA Negative1647474
Cycle 6 Week 15 — Not evaluated1073
End of Study/Early Terminiation — ADA Positive412
End of Study/Early Terminiation — Nab Positive000
End of Study/Early Terminiation — ADA Negative1467571
End of Study/Early Terminiation — Not evaluated2568
PrimaryDisease-Free Survival

DFS, defined as the time from randomization in the neoadjuvant study (Protocol TX05-03) to the documentation of a first failure, where a failure was the recurrence of breast cancer or a diagnosis of a second primary cancer.

Time frame:
Through study completion/end of treatment (Week 45).
Reported as:
Count of participants · Participants
Disease-Free Survival
ParticipantsTest Product (TX05 Only)Reference Therapy (Herceptin Only)Test Product (Herceptin/TX05 Transition)
Recurrence of Breast Cancer or a Diagnosis of a Second Primary Cancer653
No recurrence of Breast Cancer and No Diagnosis of a Second Primary Cancer1607376
Discontinued form Study842
No Post Baseline or No Evaluable Post Baseline100
No Baseline or No Evaluable Baseline Assessment000
Death000
PrimaryOverall Survival

OS, defined as the time from randomization in the neoadjuvant study (Protocol TX05-03) until death from any cause.

Time frame:
Through study completion/end of treatment (Week 45).
Reported as:
Count of participants · Participants
Overall Survival
ParticipantsTest Product (TX05 Only)Reference Therapy (Herceptin Only)Test Product (Herceptin/TX05 Transition)
Last known alive1758280
Lost to Follow-Up000
Death001

Adverse events

Collected over Adverse Events were recorded from Day 1 (Week 0) of Cycle 1 of study treatment through End of Treatment (Week 45), with the exception of any ongoing study drug-related AEs, which were to be followed until the event was resolved, considered stable, or the investigator determined the AE was no longer clinically significant.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test Product (TX05 Only)0/175 (0%)4/175 (2.3%)49/175 (28%)
Reference Therapy (Herceptin Only)0/82 (0%)3/82 (3.7%)15/82 (18.3%)
Test Product (Herceptin/TX05 Transition)1/81 (1.2%)2/81 (2.5%)15/81 (18.5%)
Most frequent serious events
Most frequent serious events
EventTest Product (TX05 Only)Reference Therapy (Herceptin Only)Test Product (Herceptin/TX05 Transition)
Hepatic failureHepatobiliary disorders0/1750/821/81
Ischaemic strokeNervous system disorders0/1750/821/81
Gastrointestinal infection/Infections and infestations0/1751/820/81
Femoral neck fracture/Injury, poisoning and procedural complications0/1751/820/81
COVID-19 pneumoniaInfections and infestations0/1751/820/81
Renal ColicRenal and urinary disorders0/1751/820/81
COVID-19Infections and infestations2/1750/820/81
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/1750/820/81
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/1750/820/81
Most frequent other events
Most frequent other events
EventTest Product (TX05 Only)Reference Therapy (Herceptin Only)Test Product (Herceptin/TX05 Transition)
Radiation Skin InjuryInjury, poisoning and procedural complications13/1755/820/81
Respiratory Tract InfectionInfections and infestations6/1752/825/81
HeadacheNervous system disorders9/1755/823/81
ArthralgiaMusculoskeletal and connective tissue disorders7/1755/822/81
Alanine Aminotransferase IncreasedInvestigations10/1752/821/81
AstheniaGeneral disorders10/1754/823/81
Aspartate Aminotransferase IncreasedInvestigations9/1751/823/81

Baseline characteristics

Age, Continuous
Age, Continuous(years)Test Product (TX05 Only)Reference Therapy (Herceptin Only)Test Product (Herceptin/TX05 Transition)Total
Mean55.3 ± 11.4353.7 ± 10.1254.0 ± 10.7154.6 ± 10.95
Sex: Female, Male
Sex: Female, Male(Participants)Test Product (TX05 Only)Reference Therapy (Herceptin Only)Test Product (Herceptin/TX05 Transition)Total
Female1758281338
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Test Product (TX05 Only)Reference Therapy (Herceptin Only)Test Product (Herceptin/TX05 Transition)Total
Hispanic or Latino29121051
Not Hispanic or Latino1467071287
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Test Product (TX05 Only)Reference Therapy (Herceptin Only)Test Product (Herceptin/TX05 Transition)Total
American Indian or Alaska Native5128
Asian23131753
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White1366457257
More than one race0000
Unknown or Not Reported114520
Hormone Receptor Status
Hormone Receptor Status(Participants)Test Product (TX05 Only)Reference Therapy (Herceptin Only)Test Product (Herceptin/TX05 Transition)Total
Positive1005048198
Negative753233140
Tumor Stage
Tumor Stage(Participants)Test Product (TX05 Only)Reference Therapy (Herceptin Only)Test Product (Herceptin/TX05 Transition)Total
Stage IIa652832125
Stage IIb784135154
Stage IIIa32131459
ECOG
ECOG(Participants)Test Product (TX05 Only)Reference Therapy (Herceptin Only)Test Product (Herceptin/TX05 Transition)Total
Grade 01425664262
Grade 129241669
Grade 20000
Grade 30000
Grade 40000
Grade 50000
Missing4217
08

Study locations

86 sites
  • Tanvex Investigational Site 1003E
    Gomel, 246012, Belarus
  • Tanvex Investigational Site 1006E
    Grodno, 230017, Belarus
  • Tanvex Investigational Site 1008E
    Lesnoy, 223040, Belarus
  • Tanvex Investigational Site 1002E
    Minsk, 220013, Belarus
  • Tanvex Investigational Site 1005E
    Mogilev, 212018, Belarus
  • Tanvex Investigational Site 1001E
    Vitebsk, 210603, Belarus
  • Tanvex Investigational Site 4001E
    Temuco, 2520598, Chile
  • Tanvex Investigational Site 4002E
    Vina del Mar, 4810469, Chile
  • Tanvex Investigational Site 5006E
    Batumi, 6000, Georgia
  • Tanvex Investigational Site 5002E
    Batumi, 6010, Georgia
  • Tanvex Investigational Site 5001E
    Tbilisi, 0159, Georgia
  • Tanvex Investigational Site 5005E
    Tbilisi, 0159, Georgia
  • Tanvex Investigational Site 5010E
    Tbilisi, 0186, Georgia
  • Tanvex Investigational Site 5008E
    Tbilisi, 112, Georgia
  • Tanvex Investigational Site 6003E
    Budapest, Hungary
  • Tanvex Investigational Site 7031E
    Nashik, Maharashtra 422002, India
  • Tanvex Investigational Site 7033E
    Ahmedabad, 380016, India
  • Tanvex Investigational Site 7019E
    Bangalore, 560027, India
  • Tanvex Investigational Site 7022E
    Belgaum, 590010, India
  • Tanvex Investigational Site 7045E
    Hyderabad, 500004, India
  • Tanvex Investigational Site 7036E
    Hyderabad, 500034, India
  • Tanvex Investigational Site 7006E
    Kolkata, 700099, India
  • Tanvex Investigational Site 7001E
    Nashik, 422002, India
  • Tanvex Investigational Site 7015E
    Pune, 411001, India
  • Tanvex Investigational Site 7017E
    Vijayawada, 520002, India
  • Tanvex Investigational Site 2109E
    Aguascalientes, 20234, Mexico
  • Tanvex Investigational Site 2103E
    Monterrey, 64000, Mexico
  • Tanvex Investigational Site 2106E
    Oaxaca, 68000, Mexico
  • Tanvex Investigational Site 2110E
    Tequisquiapan, 76750, Mexico
  • Tanvex Investigational Site 2108E
    Zapopan, 45030, Mexico
  • Tanvex Investigational Site 1101E
    Arequipa, 04001, Peru
  • Tanvex Investigational Site 1107E
    Arequipa, 04001, Peru
  • Tanvex Investigational Site 1104E
    Chiclayo, 14001, Peru
  • Tanvex Investigational Site 1112E
    Lima Cercado, 15082, Peru
  • Tanvex Investigational Site 1105E
    Lima, 15036, Peru
  • Tanvex Investigational Site 1108E
    San Borja, 41, Peru
  • Tanvex Investigational Site 1102E
    San Isidro, 15073, Peru
  • Tanvex Investigational Site 1109E
    Surquillo, 15038, Peru
  • Tanvex Investigational Site 1103E
    Trujillo, 13001, Peru
  • Tanvex Investigational Site 1211E
    Cebu city, 6000, Philippines
  • Tanvex Investigational Site 1212E
    Davao City, 8000, Philippines
  • Tanvex Investigational Site 1214E
    Makati City, 1229, Philippines
  • Tanvex Investigational Site 1209E
    Quezon City, 1101, Philippines
  • Tanvex Investigational Site 1213E
    Quezon City, 1102, Philippines
  • Tanvex Invesitgational Site 1210E
    Santo Tomas, 4234, Philippines
  • Tanvex Investigational Site 1513E
    Sochi, Krasnodar Region 354057, Russian Federation
  • Tanvex Investigational Site 1535E
    Arkhangelsk, 163045, Russian Federation
  • Tanvex Investigational Site 1531E
    Belgorod, 308010, Russian Federation
  • Tanvex Investigational Site 1502E
    Kaluga, Russian Federation
  • Tanvex Investigational Site 1505E
    Kislino, 305524, Russian Federation
  • Tanvex Investigational Site 1529E
    Krasnodar, 350040, Russian Federation
  • Tanvex Investigational Site 1512E
    Krasnoyarsk, 660133, Russian Federation
  • Tanvex Investigational Site 1530E
    Moscow, 121467, Russian Federation
  • Tanvex Investigational Site 1507E
    Moscow, Russian Federation
  • Tanvex Investigational Site 1511E
    Novosibirsk, 630099, Russian Federation
  • Tanvex Investigational Site 1503E
    Omsk, 644013, Russian Federation
  • Tanvex Investigational Site 1509E
    Omsk, 644013, Russian Federation
  • Tanvex Investigational Site 1537E
    Orenburg, 460021, Russian Federation
  • Tanvex Investigational Site 1526E
    Pesochnyy, 197758, Russian Federation
  • Tanvex Investigational Site 1510E
    Pushkin, 196603, Russian Federation
  • Tanvex Investigational Site 1521E
    Rostov-Na-Donu, 344037, Russian Federation
  • Tanvex Investigational Site 1516E
    Saint Petersburg, 191015, Russian Federation
  • Tanvex Investigational Site 1524E
    Saint Petersburg, 191104, Russian Federation
  • Tanvex Investigational Site 1525E
    Saint Petersburg, 196247, Russian Federation
  • Tanvex Investigational Site 1506E
    Saint Petersburg, 197758, Russian Federation
  • Tanvex Investigational Site 1501E
    Saint Petersburg, Russian Federation
  • Tanvex Investigational Site 1523E
    Sankt-peterburg, 191104, Russian Federation
  • Tanvex Investigational Site 1508E
    Saransk, 430032, Russian Federation
  • Tanvex Investigational Site 1534E
    Yaroslavl, 150054, Russian Federation
  • Tanvex Investigational Site 1820E
    Antonivka, 73000, Ukraine
  • Tanvex Investigational Site 1803E
    Chernihiv, 14029, Ukraine
  • Tanvex Investigational Site 1808E
    Chernihiv, 14029, Ukraine
  • Tanvex Investigational Site 1821E
    Chernivtsi, 58013, Ukraine
  • Tanvex Investigational Site 1824E
    Dnipro, 49600, Ukraine
  • Tanvex Investigational Site 1811E
    Kiev, 03115, Ukraine
  • Tanvex Investigational Site 1802E
    Kiev, 04107, Ukraine
  • Tanvex Investigational Site 1819E
    Kropyvnytskyi, 25006, Ukraine
  • Tanvex Investigational Site 1814E
    Kropyvnytskyi, 25011, Ukraine
  • Tanvex Investigational Site 1804E
    Kryvyi Rih, 50048, Ukraine
  • Tanvex Investigational Site 1815E
    Kyiv, 03022, Ukraine
  • Tanvex Investigational Site 1809E
    Kyiv, 03126, Ukraine
  • Tanvex Investigational Site 1810E
    Odesa, 65055, Ukraine
  • Tanvex Investigational Site 1806E
    Sumy, 40022, Ukraine
  • Tanvex Investigational Site 1822E
    Ternopil, 46023, Ukraine
  • Tanvex Investigational Site 1818E
    Vinnytsia, 21029, Ukraine
  • Tanvex Investigational Site 1813E
    Zaporizhzhya, 69059, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Dec 2021, 28 months.

Results were first posted in Oct 2022, 10 months after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 28 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2019
First posted
Sep 30, 2019
StartActual
Aug 20, 2019
Primary completionActual
Dec 25, 2021
CompletionActual
Mar 8, 2022
Results first posted
Oct 26, 2022
Last update
Oct 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04109391
Lead sponsor
Tanvex BioPharma USA, Inc.
Responsible party
Sponsor
First posted
Sep 30, 2019
Start date
Aug 20, 2019
Primary completion
Dec 25, 2021
Completion
Mar 8, 2022
Results posted
Oct 26, 2022
Last update
Oct 26, 2022

Study contacts

Bonnie Mills, PhD
study director · Tanvex BioPharma USA, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion